Skip to main content
FIBROGEN INC logo

FIBROGEN INC — Investor Relations & Filings

Ticker · FGEN ISIN · US31572Q8087 LEI · 549300Q914ULWWY95822 US Manufacturing
Filings indexed 1,124 across all filing types
Latest filing 2026-04-09 Regulatory Filings
Country US United States of America
Listing US FGEN

About FIBROGEN INC

https://www.fibrogen.com/

FibroGen, Inc. is a biopharmaceutical company that discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company focuses on creating innovative, first-in-class medicines for chronic and life-threatening or debilitating conditions. Its primary areas of research and development are in anemia and oncology. A key product is roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor (HIF) prolyl hydroxylase activity, developed for the treatment of anemia associated with chronic kidney disease. The company's pipeline also includes potential treatments for various cancers, such as pancreatic cancer.

Recent filings

Filing Released Lang Actions
8-K - KYNTRA BIO, INC. (0000921299) (Filer)
Regulatory Filings
2026-04-09 English
4 Filing
Director's Dealing
2026-02-05 English
4 Filing
Director's Dealing
2026-02-05 English
8-K Filing
Regulatory Filings
2026-01-07 English
Director's Dealing 2025
Director's Dealing
2025-12-09 English
Director's Dealing 2025
Director's Dealing
2025-12-09 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.